One of the easiest traps in international primary research is assuming that “plain...
Whenever analogs come up in pharma strategy, someone usually says: “But that situation...
Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on...
You’ve spent months working on the asset. The clinical strategy has been debated. The data...
Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years...
This past month, I have been immersed in obesity science, and one thing’s clear: not every...
One of the easiest traps in international primary research is assuming that “plain English” is automatically clear English. When preparing a primary...
Whenever analogs come up in pharma strategy, someone usually says: “But that situation wasn’t the same as ours.” In recent weeks, I’ve...
Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on digital cognitive assessments. Along the way, I came...
You’ve spent months working on the asset. The clinical strategy has been debated. The data have been reviewed from every angle. The...
One of the easiest traps in international primary research is assuming that “plain English” is...
Whenever analogs come up in pharma strategy, someone usually says: “But that situation wasn’t the...
Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on digital...
You’ve spent months working on the asset. The clinical strategy has been debated. The data have been...
Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took...
This past month, I have been immersed in obesity science, and one thing’s clear: not every pathway...
Intro Teams often fail not because of a lack of data, but because of research that confirms what...
It has been a quiet summer on the post front with holidays and then a few active projects keeping us...
Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics, a company...